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Background
The reason why FMF carriers may develop the disease is
still unclear. We assessed the clinical characteristics of
French FMF patients carrying a single MEFV mutation
Methods
A retrospective chart review of patients referred to us with
FMF symptoms. Systematic genetic screening of exon 2
and 10 was performed in MEFV gene. A subset of patients
was also investigated for other hereditary recurrent fevers
Results
We analysed 94 patients (sex-ratio:1). 42% were Jews and
17% were Arabs. Familial history of FMF was found in
23%, MICI in 10%, amyloidosis in 3% and Behçet in 3%.
Median age of onset was 2 y. Fever was >39°C in 80%,
duration and frequency of an attack varied (<24 h: 8%, 1–
3 d: 56%, >3 d: 36%; >2/m: 15%, 1–2 m: 48% <1 m: 37%
respectively). Peritonitis occurred in 97%, pleuritis in
25%, arthralgia in 53%; arthritis in 4 cases; skin rashes in
20%, aphtosis in 18% and lymphadenopathy in 9%.
MEFV mutation were: M694V (60%), M694I (7%).The
R92Q TRAPS mutation was retrieved in 3/21 patients
tested and the V377I MKD mutation in 1/6. Colchicine
treatment was required in 82% of them and was effective
in >90% of them. Associated diseases in these patients
were PFAPA (4), Ankylosing spondylitis (5), Crohn's dis-
ease (1) and Castleman disease (1).
Discussion
The clinical picture of MEFV heterozygotes resembles that
of homozygote patients. This study displays a wide variety
of associated diseases. Complete screening of both MEFV
and other auto-inflammatory gene mutation may increase
our understanding of disease expression.
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